Zymeworks : First Quarter 2025 Earnings Presentation

Published: 2025-05-08 20:08:39 ET ZYME

Published on 05/08/2025 at 20:08

Conference Call and Webcast

May 8, 2025

Nasdaq: ZYME | zymeworks.com

EVP, CBO and CFO

Business Update

Financial Update

Q&A

CSO

R&D Update

Q&A

Chair and CEO

Q&A

SVP Clinical Development

Q&A

3

FINANCIAL UPDATE

Leone Patterson, MBA, CPA

Executive Vice President, Chief Business and Financial Officer

4

Six posters presented at the AACR annual meeting, including:

T cell Engagers (TCE):

ZW171, a differentiated 2+1 T cell-engaging bispecific antibody

ZW209, a DLL3 targeted trispecific TCE

Antibody-Drug Conjugates (ADC)

ZW327, a novel Ly6E-targeting ADC

Developing biparatopic ADC's targeting PTK7

Poster presentations for our wholly-owned product pipeline accepted at:

American Thoracic Society annual meeting

American Society of Clinical Oncology annual meeting

ESMO Gynaecological Cancers annual meeting

Acceptance of three abstracts for zanidatamab at the ASCO annual meeting submitted by our partner, Jazz.

EMA CHMP has adopted a positive opinion recommending the approval of zanidatamab for the treatment of advanced HER2+ BTC.

Continued execution against our long-term strategy reflects the discipline, focus, and resilience of our business model.

Disclaimer

Zymeworks Inc. published this content on May 07, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 08, 2025 at 22:26 UTC.